Everything below concerns hGH fragment. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-09-19. Where a claim depends on a specific study, the study is described rather than over-claimed.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
A study of iron-deficiency among early Mongolian nomads showed that although overall rates of cribra orbitalia declined from 28.7 percent (27.8 percent of the total female population, 28.4 percent of the total male population, 75 percent of the total juvenile population) during the Bronze and Iron Ages, to 15.5 percent during the Hunnu (2209–1907 BP) period, the rate of females with cribra orbitalia remained roughly the same, while incidence among males and children declined (29.4 percent of the total female population, 5.3 percent of the total male population, and 25 percent of the juvenile population had cribra orbitalia). This study hypothesized that adults may have lower rates of cribra orbitalia than juveniles because lesions either heal with age or lead to death. Higher rates of cribia orbitalia among females may indicate lesser health status, or greater survival of young females with cribia orbitalia into adulthood.
==== Education ==== NCCAM also funds education and outreach programs. Despite the negative findings on the effectiveness of distance healing, NCCAM awarded $180,000 to a consultant to develop an Internet-based wellness program on the healing by Qigong.
3K3A-Activated Protein C (3K3A-APC) is an experimental drug for the treatment of stroke developed by ZZ Biotech, a company founded by Berislav Zlokovic. It is a genetically engineered variant of activated protein C designed to reduce anticoagulant activity while preserving its cytoprotective and anti-inflammatory properties. This recombinant protein is created by substituting three lysine residues with alanines, thereby minimizing the risk of bleeding associated with native activated protein C. 3K3A-APC exerts its therapeutic effects by targeting protease-activated receptor 1 (PAR1) pathway. A Phase 3 clinical trial was scheduled to start when the NIH paused the trial on November 16, 2023, due to concerns about falsification of data in the studies supporting the clinical trial. The drug was also being assessed for the treatment of Alzheimer's disease, and is currently being evaluated by Dermatherix for wound care.
The phenolic ring that is indispensable for binding to estrogen receptor The ring of isoflavones mimicking a ring of estrogens at the receptors binding site Low molecular weight similar to estrogens (MW=272) Distance between two hydroxyl groups at the isoflavones nucleus similar to that occurring in estradiol Optimal hydroxylation pattern In addition to interaction with ERs, phytoestrogens may also modulate the concentration of endogenous estrogens by binding or inactivating some enzymes, and may affect the bioavailability of sex hormones by depressing or stimulating the synthesis of sex hormone-binding globulin (SHBG). Emerging evidence shows that some phytoestrogens bind to and transactivate peroxisome proliferator-activated receptors (PPARs). In vitro studies show an activation of PPARs at concentrations above 1 μM, which is higher than the activation level of ERs. At the concentration below 1 μM, activation of ERs may play a dominant role. At higher concentrations (>1 μM), both ERs and PPARs are activated. Studies have shown that both ERs and PPARs influence each other and therefore induce differential effects in a dose-dependent way. The final biological effects of genistein are determined by the balance among these pleiotrophic actions.
Sources: en.wikipedia.org
The use of RdRp plays a major role in RNA interference in eukaryotes, a process used to silence gene expression via small interfering RNAs (siRNAs) binding to mRNA rendering them inactive. Eukaryotic RdRp becomes active in the presence of dsRNA, and is less widely distributed than other RNAi components as it lost in some animals, though still found in C. elegans, P. tetraurelia, and plants. This presence of dsRNA triggers the activation of RdRp and RNAi processes by priming the initiation of RNA transcription through the introduction of siRNAs. In C. elegans, siRNAs are integrated into the RNA-induced silencing complex, RISC, which works alongside mRNAs targeted for interference to recruit more RdRps to synthesize more secondary siRNAs and repress gene expression. Spiegelman's Monster NS5B inhibitor RNA+Replicase at the U.S. National Library of Medicine Medical Subject Headings (MeSH) EC 2.7.7.48
As a result, more affordable headsets designed to accommodate mobile devices were also released, using the devices to create the stereoscopic display, some of the positioning functions, and other VR tracking embedded in the additional hardware. On June 25, 2014, Google officially introduced Google Cardboard, an inexpensive headset package that constructed from cardboard for use with Android phones; the completed headset creates the necessary visual space to support stereoscopic view from the phone's display. Samsung, in conjunction with Oculus, released the Samsung Gear VR in 2015 to support its Samsung Galaxy smartphones; services for the Gear VR ended in 2020. Nintendo released the Nintendo Labo VR Kit in 2019 as part of its Labo series of toys-to-life cardboard products. A handful of Nintendo Switch games support Labo VR functionality, such as the 2017 games Super Mario Odyssey and The Legend of Zelda: Breath of the Wild. Despite the availability of low-cost hardware for VR, the technology had still not taken off for video games by 2018 as had been expected when the Oculus Rift was announced. This was attributed to the lack of a killer application, a game that would drive people to buy the hardware to play it. There had been several games from smaller studios that had been considered successful, such as Superhot VR and Beat Saber, but the triple-A studios had not ventured into the area. Sales of VR hardware had been steadily increasing since 2016, but were still under 10 million units by 2018, and there were signs manufacturers were starting to back off in this area.
Bromocriptine is a partial agonist of the dopamine D2 receptor. It also interacts with other dopamine receptors and with various serotonin and adrenergic receptors. Bromocriptine has additionally been found to inhibit the release of glutamate by reversing the glutamate transporter 1 (GLT-1; EAAT2). Despite acting as a serotonin 5-HT2A receptor agonist, bromocriptine is described as non-hallucinogenic. As a silent antagonist of the serotonin 5-HT2B receptor, bromocriptine has been said not to pose a risk of cardiac valvulopathy. This is in contrast to other ergolines acting instead as 5-HT2B receptor agonists such as cabergoline and pergolide but is similar to lisuride which likewise acts as a 5-HT2B receptor antagonist. However, in other research, bromocriptine has subsequently been found to be a partial agonist of the serotonin 5-HT2B receptor and has been associated with cardiac valvulopathy and related complications. In any case, bromocriptine seems to have lower risk than certain other drugs.
== Applications == Due to its proteinous nature, silk peptide is susceptible to the action of proteolytic enzymes, making it digestible and biocompatible; and because of properties like its gelling ability, moisture retention capacity and skin adhesion, it has numerous medical, pharmaceutical and cosmetic applications.
In 1986 and 1987, Transkei, a larger, wealthier, and more populous entity, undertook a series of military raids on Ciskei, and attempted to seize control of Ciskei. One of these raids was an attack on leader Lennox Sebe's compound, with the apparent goal of taking him hostage, in order to force a merger of the two Bantustans. Transkei had previously granted sanctuary to Lennox Sebe's estranged brother, Charles, the former head of Ciskei's security forces, who had been imprisoned in Ciskei on charges of sedition, in addition to previously kidnapping Lennox Sebe's son. The South African government ostensibly intervened to warn the Transkei government off. However, during a later meeting of the Truth and Reconciliation Commission, it was revealed that the plan to amalgamate the Transkei and Ciskei into a proposed Xhosaland, as well as the freeing of Charles Sebe from prison, had been carried out by South African security forces linked to the Civil Cooperation Bureau, in order to consolidate an anti-ANC front in the Eastern Cape region, as part of the abortive Operation Katzen.
Sources: en.wikipedia.org
Glyceollin synthase is an enzyme that catalyzes the last committed step in glyceollin biosynthesis. It has been classified as a cytochrome dependent monooxygenase. It cyclizes a prenyl residue in its starting materials to convert glyceollidins (I and II) into glyceollins (I - III). This enzyme catalyzes three chemical reactions, for example:
== Use as a deterrent == For many scaled insects of the genus Dactylopius, carminic acid, thoroughly documented by Thomas Eisner, has been shown to be a highly potent feeding deterrent against ants. In Eisner's 1980 paper, he notes that the red colour of the carminic acid released when the cochineals are crushed could also be a visual aposematic deterrent for predators as well. However, he notes that tests have not been done on vertebrates to provide any support to that theory. In the same paper however, Eisner mentions that cochineals were bitter when tasted by humans.
These are taxonomy (discovering, describing, and naming species), nomenclature (ensuring the correct and universally accepted naming of those species), phylogeny (inferring the evolutionary relationships among species), and classification (arranging species into higher-order groups like genera, families, and orders). These activities are interdependent. For example, naming a new species (an act of taxonomy) automatically places it within a genus, implicitly hypothesizing a relationship to other members of that genus. Likewise, classifications are continually revised as phylogenetic studies uncover more natural (evolutionarily valid) groupings. A guiding principle in modern systematics is to ensure that each recognized group includes all descendants of one common ancestor (a condition called monophyly). Groupings based only on superficial similarity rather than real ancestry are considered artificial; when studies reveal such cases, the groups are reorganized to reflect true evolutionary lineages. In practice this means many traditional lichen groups defined by convenient field characters (such as all "crustose" lichens or all lichens with a certain type of fruiting body) have been dismantled, and their members redistributed, to ensure that each genus or family reflects a single evolutionary lineage. Lichen systematics has been revolutionized in recent decades by molecular biology and genomics. DNA sequencing now allows researchers to resolve cryptic species and deep evolutionary relationships that were impossible to discern from morphology alone.
== Safety == Although argon is non-toxic, it is 38% more dense than air and therefore considered a dangerous asphyxiant in closed areas. It is difficult to detect because it is colorless, odorless, and tasteless. A 1994 incident, in which a man was asphyxiated after entering an argon-filled section of oil pipe under construction in Alaska, highlights the dangers of argon tank leakage in confined spaces and emphasizes the need for proper use, storage and handling.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.